San Francisco, CA—Percutaneous closure of the patent ductus arteriosus (PDA) in children using a novel device is safe and effective, according to a prospective study presented in a featured clinical ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus ...
A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...
In 2019, the U.S. Food and Drug Administration approved the first PDA occlusion device for infants as small as 700 grams, leading to rapid adoption of tcPDA in premature infants. Catheter-based ...
The ductus arteriosus is a normal vessel in the fetus that connects the pulmonary artery and the aorta. It allows the fetal blood flow to bypass the lungs, which are not used in utero. The ductus ...
Kolkata: A premature newborn girl, weighing only 720 g, underwent a cardiac procedure—that is usually considered for babies only after they have attained at least 5 kg weight—on the eighth day after ...
Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, according to research ...
The pea-sized device is a self-expanding wire mesh that is inserted through an incision in the leg and guided through vessels to the heart, where it is placed to seal the opening. The Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results